Medical Management of Toxic Megacolon
暂无分享,去创建一个
[1] A. Griffiths,et al. Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: Canadian Association of Gastroenterology. , 2014, Gastroenterology.
[2] P. Rutgeerts,et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. , 2014, Gastroenterology.
[3] G. Radford-Smith,et al. Outcomes of salvage therapy for steroid‐refractory acute severe ulcerative colitis: ciclosporin vs. infliximab , 2013, Alimentary pharmacology & therapeutics.
[4] Laurent Beaugerie,et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. , 2013, Journal of Crohn's & colitis.
[5] John T. Chang,et al. Strategies for the care of adults hospitalized for active ulcerative colitis. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[6] J. Gisbert,et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial , 2012, The Lancet.
[7] S. Vermeire,et al. Second European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Current management , 2012 .
[8] R. Erichsen,et al. Thirty-day mortality after elective and emergency total colectomy in Danish patients with inflammatory bowel disease: a population-based nationwide cohort study , 2012, BMJ Open.
[9] J. Gisbert,et al. Infliximab salvage therapy after failure of ciclosporin in corticosteroid‐refractory ulcerative colitis: a multicentre study , 2012, Alimentary pharmacology & therapeutics.
[10] A. Kornbluth,et al. Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee , 2010, The American Journal of Gastroenterology.
[11] A. Gasbarrini,et al. Infliximab in severe ulcerative colitis: short‐term results of different infusion regimens and long‐term follow‐up , 2007, Alimentary pharmacology & therapeutics.
[12] S. Xiao,et al. Meta‐analysis: the utility and safety of heparin in the treatment of active ulcerative colitis , 2007, Alimentary pharmacology & therapeutics.
[13] S. Danese,et al. Inflammation and Coagulation in Inflammatory Bowel Disease: The Clot Thickens , 2007, The American Journal of Gastroenterology.
[14] Å. Danielsson,et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. , 2005, Gastroenterology.
[15] P. Beck,et al. A new look at toxic megacolon: an update and review of incidence, etiology, pathogenesis, and management , 2003, American Journal of Gastroenterology.
[16] P. Rutgeerts,et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. , 2003, Gastroenterology.
[17] A. Kornbluth,et al. Ulcerative colitis practice guidelines in adults , 1997 .
[18] D. Jewell,et al. Predicting outcome in severe ulcerative colitis. , 1996, Gut.
[19] D. Jewell,et al. Intensive intravenous regimen for severe attacks of ulcerative colitis. , 1974, Lancet.
[20] R. Prescott,et al. An Experience of Ulcerative Colitis , 1970 .
[21] W. Card,et al. An experience of ulcerative colitis. I. Toxic dilation in 55 cases. , 1969, Gastroenterology.